Phathom Pharmaceuticals Inc (NASDAQ: PHAT) kicked off on Monday, down -5.00% from the previous trading day, before settling in for the closing price of $6.60. Over the past 52 weeks, PHAT has traded in a range of $4.07-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1600.29% over the last five years. While this was happening, its average annual earnings per share was recorded 24.15%. With a float of $38.63 million, this company’s outstanding shares have now reached $68.52 million.
The firm has a total of 427 workers. Let’s measure their productivity. In terms of profitability, gross margin is 85.57%, operating margin of -502.18%, and the pretax margin is -605.09%.
Phathom Pharmaceuticals Inc (PHAT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 44.53%, while institutional ownership is 60.25%. The most recent insider transaction that took place on Mar 13 ’25, was worth 44,200. In this transaction Director of this company bought 10,000 shares at a rate of $4.42, taking the stock ownership to the 85,500 shares. Before that another transaction happened on Jan 21 ’25, when Company’s CFO and CBO sold 6,583 for $6.59, making the entire transaction worth $43,371. This insider now owns 93,546 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 24.15% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Take a look at Phathom Pharmaceuticals Inc’s (PHAT) current performance indicators. Last quarter, stock had a quick ratio of 4.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.35, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Analysing the last 5-days average volume posted by the [Phathom Pharmaceuticals Inc, PHAT], we can find that recorded value of 1.03 million was lower than the volume posted last year of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 79.67%. Additionally, its Average True Range was 0.55.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 14.26%, which indicates a significant decrease from 78.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.75% in the past 14 days, which was higher than the 104.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.86, while its 200-day Moving Average is $10.92. Now, the first resistance to watch is $6.57. This is followed by the second major resistance level at $6.86. The third major resistance level sits at $7.07. If the price goes on to break the first support level at $6.07, it is likely to go to the next support level at $5.86. Now, if the price goes above the second support level, the third support stands at $5.57.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
The company with the Market Capitalisation of 436.62 million has total of 69,637K Shares Outstanding. Its annual sales at the moment are 55,250 K in contrast with the sum of -334,330 K annual income. Company’s last quarter sales were recorded 29,660 K and last quarter income was -74,450 K.
